Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases
| Autor: | Yogeshvar N. Kalia, Robert F. Kelley, Stefan T. Yohe, Jeffrey Aaronson, Whitney Shatz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Drug
medicine.medical_specialty Standard of care Eye Diseases genetic structures media_common.quotation_subject Macular Degeneration/drug therapy Pharmaceutical Science Biological Availability 02 engineering and technology Residence time (fluid dynamics) Eye 030226 pharmacology & pharmacy 03 medical and health sciences Macular Degeneration 0302 clinical medicine Drug Delivery Systems medicine Animals Humans Intensive care medicine Ocular bioavailability Eye/metabolism media_common ddc:615 business.industry 021001 nanoscience & nanotechnology eye diseases Intravitreal Injections sense organs 0210 nano-technology business Eye Diseases/drug therapy |
| Zdroj: | Expert Opinion on Drug Delivery, Vol. 16, No 1 (2019) pp. 43-57 |
| ISSN: | 1742-5247 |
| Popis: | Treating posterior eye diseases has become a major area of focus for pharmaceutical and biotechnology companies. Current standard of care for treating posterior eye diseases relies on administration via intravitreal injection. Although effective, this is not without complications and there is great incentive to develop longer-acting therapeutics and/or sustained release delivery systems. Here, we present an overview of emerging technologies for delivery of biologics to the back of the eye.Posterior eye diseases, intravitreal injection, age-related macular degeneration, anti-VEGF, ocular pharmacokinetics, novel technologies to extend half-life,Posterior eye diseases are a worldwide public health issue. Although anti-VEGF molecules represent a major advance for treating diseases involving choroidal neovascularization, frequent injection can be burdensome for patients and clinicians. There is a need for effective and patient-friendly treatments for posterior eye diseases. Many technologies that enable long-acting delivery to the back of the eye are being evaluated. However, successful development of novel therapies and delivery technologies is hampered by a multitude of factors, including patient education, translatability of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|